The Prometheus League
Breaking News and Updates
- Abolition Of Work
- Ai
- Alt-right
- Alternative Medicine
- Antifa
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ascension
- Astronomy
- Atheism
- Atheist
- Atlas Shrugged
- Automation
- Ayn Rand
- Bahamas
- Bankruptcy
- Basic Income Guarantee
- Big Tech
- Bitcoin
- Black Lives Matter
- Blackjack
- Boca Chica Texas
- Brexit
- Caribbean
- Casino
- Casino Affiliate
- Cbd Oil
- Censorship
- Cf
- Chess Engines
- Childfree
- Cloning
- Cloud Computing
- Conscious Evolution
- Corona Virus
- Cosmic Heaven
- Covid-19
- Cryonics
- Cryptocurrency
- Cyberpunk
- Darwinism
- Democrat
- Designer Babies
- DNA
- Donald Trump
- Eczema
- Elon Musk
- Entheogens
- Ethical Egoism
- Eugenic Concepts
- Eugenics
- Euthanasia
- Evolution
- Extropian
- Extropianism
- Extropy
- Fake News
- Federalism
- Federalist
- Fifth Amendment
- Fifth Amendment
- Financial Independence
- First Amendment
- Fiscal Freedom
- Food Supplements
- Fourth Amendment
- Fourth Amendment
- Free Speech
- Freedom
- Freedom of Speech
- Futurism
- Futurist
- Gambling
- Gene Medicine
- Genetic Engineering
- Genome
- Germ Warfare
- Golden Rule
- Government Oppression
- Hedonism
- High Seas
- History
- Hubble Telescope
- Human Genetic Engineering
- Human Genetics
- Human Immortality
- Human Longevity
- Illuminati
- Immortality
- Immortality Medicine
- Intentional Communities
- Jacinda Ardern
- Jitsi
- Jordan Peterson
- Las Vegas
- Liberal
- Libertarian
- Libertarianism
- Liberty
- Life Extension
- Macau
- Marie Byrd Land
- Mars
- Mars Colonization
- Mars Colony
- Memetics
- Micronations
- Mind Uploading
- Minerva Reefs
- Modern Satanism
- Moon Colonization
- Nanotech
- National Vanguard
- NATO
- Neo-eugenics
- Neurohacking
- Neurotechnology
- New Utopia
- New Zealand
- Nihilism
- Nootropics
- NSA
- Oceania
- Offshore
- Olympics
- Online Casino
- Online Gambling
- Pantheism
- Personal Empowerment
- Poker
- Political Correctness
- Politically Incorrect
- Polygamy
- Populism
- Post Human
- Post Humanism
- Posthuman
- Posthumanism
- Private Islands
- Progress
- Proud Boys
- Psoriasis
- Psychedelics
- Putin
- Quantum Computing
- Quantum Physics
- Rationalism
- Republican
- Resource Based Economy
- Robotics
- Rockall
- Ron Paul
- Roulette
- Russia
- Sealand
- Seasteading
- Second Amendment
- Second Amendment
- Seychelles
- Singularitarianism
- Singularity
- Socio-economic Collapse
- Space Exploration
- Space Station
- Space Travel
- Spacex
- Sports Betting
- Sportsbook
- Superintelligence
- Survivalism
- Talmud
- Technology
- Teilhard De Charden
- Terraforming Mars
- The Singularity
- Tms
- Tor Browser
- Trance
- Transhuman
- Transhuman News
- Transhumanism
- Transhumanist
- Transtopian
- Transtopianism
- Ukraine
- Uncategorized
- Vaping
- Victimless Crimes
- Virtual Reality
- Wage Slavery
- War On Drugs
- Waveland
- Ww3
- Yahoo
- Zeitgeist Movement
-
Prometheism
-
Forbidden Fruit
-
The Evolutionary Perspective
Monthly Archives: January 2022
Silencing a faulty gene may uncover clues to rare forms of ALS – National Institutes of Health
Posted: January 27, 2022 at 11:55 pm
News Release
Monday, January 24, 2022
NIH-funded preclinical study identifies potential therapeutic approach to treat ALS.
Using an experimental drug, researchers were able to suppress a mutated amyotrophic lateral sclerosis (ALS) gene. Studies in mice demonstrate that the therapy could show promise in treating rare, aggressive forms of ALS caused by mutations in the fused in sarcoma (FUS) gene. The study, published in Nature Medicine, was funded in part by the National Institute for Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.
The study models how promising gene-targeting therapies can move expeditiously from pre-clinical development to clinical testing, said Amelie Gubitz, Ph.D., program director at NINDS. There is a desperate need for innovative approaches to treating ALS.
ALS, also known as Lou Gehrigs disease, is a fatal neurological disorder that causes the degeneration of motor neurons in the brain and spinal cord. People with ALS rapidly lose muscle strength and eventually their ability to move, swallow, and breathe. Most cases of ALS are sporadic, but at least 10% of cases are familial, or due to mutations in various genes. Mutations in the gene FUS cause severe forms of ALS, referred to as FUS-ALS, including a rare type that begins in adolescence or young adulthood.
In the study, Neil Shneider, M.D., Ph.D., the Claire Tow Associate Professor of Motor Neuron Disorders and Director of the Eleanor and Lou Gehrig ALS Center at Columbia University, New York City, and his team delayed the onset of motor neuron degeneration in mice by using an antisense oligonucleotide drug designed to silence FUS by blocking cells from making specific proteins. Following encouraging results, they administered the drug to a patient with ALS.
Compared to normal mice, mice with a mutated FUS gene had higher levels of insoluble FUS and other ALS-related proteins in their brains and spinal cords. Mice with higher doses of mutant FUS in motor neurons experienced rapid neurodegeneration that began early in life, much like FUS-ALS patients.
The study establishes a mouse model that is highly disease-relevant, said Dr. Shneider. In mice, we found that FUS toxicity was due to a gain of function and was dose-dependent, suggesting that we could treat FUS-ALS by silencing the FUS gene.
In 2019 Dr. Shneider met an individual with ALS in search of therapies that may help her disease. Inspired by her story, Dr. Shneider teamed up with a pharmaceutical company to develop a personalized therapy designed to target the FUS mutation.
In mice, injecting a single dose of the drug into the ventricles, fluid-filled spaces surrounding the brain, delayed the onset of inflammation and motor neuron degeneration by six months. The drug also knocked down levels of FUS by 50% to 80% in the brain and spinal cord. Following drug administration, insoluble forms of other ALS-associated proteins were also cleared.
Under a compassionate use protocol reviewed by the U.S. Food and Drug Administration, Dr. Shneider administered the drug to the patient it had been designed for. The patient received repeated infusions of the drug into her spinal canal for 10 months. During the treatment, the patients rate of motor function deterioration slowed. The patient tolerated the treatment well and there were no medically adverse effects.
The study is an example of a precision medicine, bench-to-bedside effort, said Dr. Shneider. We began with the mouse model to establish a rationale for the drug, conducted efficacy studies in the mouse, moved the drug into a human, and collected valuable data that was ultimately used to support a larger Phase 3 clinical trial.
Treatment began more than six months after clinical onset, by which time the disease had already significantly advanced. As is typical with juvenile-onset FUS-ALS, the disease progressed rapidly, and the patient died from complications of the disease.
By studying the patients brain and spinal cord tissue, researchers found that the drug silenced FUS throughout the nervous system and reversed the toxic nature of FUS and other disease-related proteins. Compared to tissue from untreated FUS-ALS patients and healthy controls, FUS protein aggregatesa pathological hallmark of this form of ALSwere sparse, suggesting that they may have been cleared by the drug. Tissue samples were provided by the New York Brain Bank of Columbia University.
The protein made from the FUS gene has been shown to be important for various cellular processes. Prior studies in mice suggest that FUS mutations result in the production of an abnormal protein that forms clumps, or aggregates, leading to motor neuron damage. By targeting the faulty gene in a way that suppresses toxic FUS activity, gene silencing products like the antisense oligonucleotide drug could potentially reduce or prevent disease progression.
The results were used to support a clinical trial testing the drug in patients with FUS-ALS (NCT04768972).
This study was supported by grants from the NIH (NS106236), Nancy Perlman, Tom Klingenstein, and the Judith and Jean Pape Adams Charitable Foundation.
NINDSis the nations leading funder of research on the brain and nervous system.The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.
About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
NIHTurning Discovery Into Health
Korobeynikov, V.A., et al. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nature Medicine, January 24, 2022. DOI: 10.1038/s41591-021-01615-z
###
Link:
Silencing a faulty gene may uncover clues to rare forms of ALS - National Institutes of Health
Posted in Gene Medicine
Comments Off on Silencing a faulty gene may uncover clues to rare forms of ALS – National Institutes of Health
5 Explosive Space Stocks to Buy in 2022 and Beyond – Motley Fool
Posted: at 11:55 pm
Space is a new and exciting industry with potential both now and in the future. According to a report by Morgan Stanley, the space industry could grow from $400 billion to more than $1 trillion by 2040, which doesn't even factor in new markets like space tourism. How do investors capture this upside? Several companies are beginning to build their contributions to this new market.
Investors need to understand that such a young industry carries many risks, but these five companies can generate significant returns if things work out well over the long term.
Image source: Getty Images.
Sometimes it's hard to believe, but the day is coming when people can tour space. Virgin Galactic Holdings (NYSE:SPCE) is helping build the space tourism industry. Its spacecraft is designed for suborbital flights, leaving the Earth's atmosphere but not entering orbit. These flights produce a short duration of weightlessness before coming back down.
The company sells tickets for future flights at $454,000 per seat but has more test flights to complete before beginning customer flights. The company's most recent test was a successful flight in July 2021, when founder Richard Branson joined the ship's crew. The long-term potential for Virgin Galactic is a fleet expansion and mastery of the technology that can make the price to fly affordable for more customers, bringing space tourism into the mainstream. The stock's small $2.6 billion market cap leaves a lot of room for upside if Virgin Galactic is successful.
If there is a space industry, how will we process the payments that flow back and forth? Payment processing company Shift4 Payments (NYSE:FOUR) could help answer that question. Hotels, entertainment businesses, and restaurants across the country use Shift4's platform.
In its report, Morgan Stanley believes that satellite broadband, satellite-delivered internet, could contribute between 50%-70% of the space industry's projected growth. Elon Musk's SpaceX has invested heavily to build Starlink, its upcoming broadband business. Shift4 has partnered with SpaceX to support it with its payment services. Shift4's management estimates this addressable market as being worth between $100 billion and $500 billion globally. Shift4's satellite broadband exposure andgrowing payments business could fuel growth over the years ahead.
Space is a complex industry, and companies like the industrial technology business Trimble (NASDAQ:TRMB) can advance the development of space with its software solutions that help its customers use data information to run their operations. For example, it can use satellite data to help customers use their physical assets most effectively. Its primary businesses concentrate on applications like buildings and infrastructure, geospatial data, commodities and utilities, and transportation.
For instance, the company's technology helps farmers maximize their crop harvest. Trimble's ability to simplify parts of these complex industries and applicationscould make it a natural fit for the space industry as it grows over time. The immaturity of space could make Trimble a good stock for broad exposure, and it happens to be the top holding in ARK's space-focused ARK Space Exploration & Innovation ETF.
Aerospace and defense company Lockheed Martin (NYSE:LMT) is a natural fit in the space industry, thanks to its vast experience in rockets and propulsion gained from making various weapons systems and vehicles for the U.S. military. It has a space business segment -- including satellites, space transportation, and defense systems -- that accounted for almost a fifth of total revenue in 2020.
President Donald Trump created the Space Force in late 2019, a new division of the U.S. military. Suppose space eventually becomes a new arena for geopolitical tension. In that case, Lockheed Martin's existing relationships and experience in the space industry could help its space segment grow as a part of the company's overall business.
Satellites are gaining more use as technology advances, helping us transmit information between space and Earth at faster speeds. BlackSky Technology (NYSE:BKSY) is a geospatial-data company that's building a network of satellites to perform rapid surveillance of the planet's landscape through its software-as-a-service platform. It can generate and transmit imagery in approximately 90 minutes; its customers include U.S. intelligence agencies and commercial customers in commodities and insurance.
It's a young company competing against other satellite companies in the market. Still, BlackSky's $2.5 billion business pipeline gives the company predictable revenue over the next few years. Investors will want to keep an eye on execution to see that backlogged business converts to billed revenue, and that BlackSky successfully expands its satellite fleet over time. Its market cap is just $370 million, so the upside is sizable if things work out.
This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
Read more here:
5 Explosive Space Stocks to Buy in 2022 and Beyond - Motley Fool
Posted in Space Exploration
Comments Off on 5 Explosive Space Stocks to Buy in 2022 and Beyond – Motley Fool
Their DNA Hides a Warning, but They Dont Want to Know What It Says – The New York Times
Posted: at 11:55 pm
I was like, wait a minute. Where is this information going? How will it be utilized? she later asked. I dont know if there are any implications for life and health insurance for me or my family, but why risk it?
What should happen when researchers, while sequencing a participants DNA as part of a large study, discover gene variants that increase the risk for conditions that might be prevented with medical treatment or surveillance? Some researchers believe they have an obligation to find the participants often years after they provided a DNA sample contact them, and tell them what they have found. But, some research subjects, like Ms. Konstadt, feel they have a right not to know. Is it ethical for doctors to let them insist they can opt out of learning more without first knowing the particular risk they are facing?
For Dr. Robert Green, an investigator for the biobank with Ms. Konstadts DNA, the Mass General Brigham Biobank, and author of a recent paper about its policies, the answers are clear. The consent form for the biobank tells participants that if the researchers find a worrisome variant, and if there is an intervention that can reduce risk, the participants will be contacted. There will be seven attempts to reach participants calls and letters before the team gives up.
We are offering the information, not forcing participants to accept it, said Dr. Green, who is also a geneticist and professor of medicine at Harvard. If you dont answer the phone or decide when offered that you dont want to hear anything more, or even hang up on us when we call, then thats your choice.
Dr. Green and his colleagues point out that the possibility of being contacted was in the consent form:
While you should not expect to receive any results from your participation in this research, if experts from the Biobank decide that research results from your sample are of high medical importance, we will attempt to contact you. In some situations, follow up testing might be needed in a certified clinical lab. You and your medical insurer may be responsible for the costs of these tests and any follow up care, including deductibles and co-payments.
But some, like Ms. Konstadt, did not notice that clause when signing the form.
Out of more than 36,000 participants, whose DNA its researchers analyzed, the Mass General Brigham Biobank found 425 with worrisome gene variants whose effects could be ameliorated by depending on the genes enhanced cancer surveillance or aggressive medical treatments to lower cholesterol levels, for example.
See the original post here:
Their DNA Hides a Warning, but They Dont Want to Know What It Says - The New York Times
Posted in Gene Medicine
Comments Off on Their DNA Hides a Warning, but They Dont Want to Know What It Says – The New York Times
Venture into the unknown – Los Angeles Times
Posted: at 11:55 pm
Everyone is always saying that we should get out of our comfort zones, but what does that actually mean? For me, it means to explore the unknown and its in the unknown that we can really grow and learn.
Through exploration of the unknown, humanity has been able to develop opportunities for success in every aspect of our society.
The subjects that students learn in science class today are derived from the exploration of the unknown. Without the great scientists and the research theyve committed themselves to, we would still be stuck in a state of perpetual stagnation.
For example, one of historys greatest scientists, first astronomers and initiator of our current space exploration programs was Galileo Galilei. Through careful planning and measurements along with a great deal of imagination, Galileo was able to create and perfect the telescope, a tool which has benefited us in space exploration for centuries.
Later he influenced many other leading scientists, such as Kepler, Newton, and our current NASA program (which has named a satellite after him), to continue his studies of the unknown universe. By taking the initiative and stepping into the investigation of the unknown, Galileo and many other noteworthy scientists were able to make a name for themselves and begin a new age of exploration, and human science will forever be in their debt.
However, the exploration of the unknown isnt limited to just academic values and knowledge. Revolutionists in both art and music have created entire eras of art, each being significantly different than the one before.
According to the National Gallery of Art, Pablo Picasso, founder of the art style Cubism, is a prime example of someone who spent their career changing what humanity knows of art. Although he was a conventional artist at the beginning of his career, his shift into what is now his most well known style of art is what made him influential.
Despite the fact that his art caused much controversy due to its unconventional depictions of what a normal painting should look like, by venturing into a new territory of art and exploring every corner of it, he was able to shape the concept of modern art.
An example of a pioneer in music is the well-known musician Louis Armstrong, who is credited with being one of the first and most prominent jazz musicians. As reported by the Louis Armstrong House, Armstrong started off rough with a difficult childhood, but he went on to become the first major jazz soloist and one of the most influential musicians of the twentieth century by producing a distinctly different style of trumpeting and incorporating a more formal yet loose style of swinging jazz that revolutionized the genre.
By breaking away from the constraints of normality, these artists and composers were able to bring about lasting changes and developments in the industry.
Not only can exploring the unknown benefit society as a whole, but it can also benefit one personally. When I was seven, I had taken an interest in rock climbing. On my eighth birthday, I asked my parents to hold my party at a local climbing gym. It would be my first time ever trying rock climbing.
Upon entering the facility with my friends, many of them decided that the feat was too scary for them. Being an adventurous third grader, I was determined to scale my first wall right then and there. However, while waiting in line for my turn, I began to get cold feet.
What if the rope snaps? What if I embarrass myself while trying to be cool?
Thoughts of doubt plagued my mind and soon it was my turn to start the climb. I was about to bail out on my chance when I realized that doubting myself into not partaking in an interest of mine was something that I was going to regret for years to come.
I hyped myself up for the climb and slowly started to scale the wall. About a quarter of the way through, I realized that I really enjoyed the experience and I started to climb faster. When I reached the top, I felt a certain sense of accomplishment that I wouldnt have felt if I had bailed out from the start.
To top my already proud self, the spotter who was handling the pulley gear told me that my climb was one of the best that shed ever seen from a junior and that I should consider continuing the sport.
From this experience, I learned that, although stepping out of my comfort zone and venturing out into the unknown was frightening, without the experience, I might have never found an interest that I was truly passionate about and even had a talent in.
The exploration of the unknown has provided the opportunity for the world to improve and augment itself in science, art, and beyond. Personally, it has definitely broadened my world and opened the doors to new experiences and growth.
What does the unknown have to offer you?
Follow this link:
Posted in Space Exploration
Comments Off on Venture into the unknown – Los Angeles Times
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) -…
Posted: at 11:55 pm
-If successful, BridgeBios investigational gene therapy BBP-631 would be the first therapy for CAH to restore the bodys hormone and steroid balance by enabling people with CAH to make their own cortisol and aldosterone
-Initial Phase 1/2 data readout anticipated in the second half of 2022
-BridgeBios gene therapy portfolio also includes a clinical stage program for Canavan disease and preclinical programs for classic galactosemia, TMC1 hearing loss, tuberous sclerosis types 1 and 2, cystinuria and a genetic dilated cardiomyopathy
PALO ALTO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient has been dosed in ADventure, its Phase 1/2 clinical trial of BBP-631, an investigational adeno-associated virus (AAV) 5 gene therapy for the treatment of classic congenital adrenal hyperplasia (CAH). CAH is one of the most prevalent genetic diseases, with more than 75,000 cases estimated in the United States and European Union.
Dosing the first patient in our CAH trial is a landmark milestone and we are grateful for the support from the medical and patient communities who helped us reach this moment. For more than 50 years people living with CAH have had the same limited standard of care lifelong daily steroid replacement treatment. Our investigational gene therapy offers patients a potential single-dose intervention designed to restore their bodys hormone and steroid balance by making their own cortisol and aldosterone, said Eric David, M.D., J.D., CEO at BridgeBio Gene Therapy. This is the second gene therapy trial we have initiated in less than four months, and we are excited to advance this trial and our other gene therapy programs in the hope of improving patients lives.
Adults, children and families affected by CAH experience the daily burden of the disease and often, unfortunately, the side effects and morbidities associated with the current treatment regimens. As an endocrinologist, its incredibly exciting to reimagine a new approach to treating this disease, added Adam Shaywitz, M.D., Ph.D., chief medical officer at BridgeBio Gene Therapy. Adrenas Therapeutics, the affiliate company of BridgeBio focused on developing BBP-631 for CAH, is part of BridgeBio Gene Therapys portfolio.
The Phase 1/2 open-label study is designed to evaluate the safety, tolerability and pharmacodynamic activity of the companys AAV5 gene therapy, BBP-631, in adults with classic CAH. In the initial dose-finding phase of the study, each subject will receive a single intravenous (IV) infusion. The primary outcomes of the study are safety, as well as change from baseline in endogenous cortisol levels which BBP-631 has the unique potential to restore. Change from baseline in steroid biomarkers for hydroxyprogesterone (17-OHP) levels and androstenedione (A4) levels will also be measured. Preclinical proof-of-concept data have shown the approach provides efficient and persistent delivery of functional 21-hydroxylase (21-OH) enzyme to the adrenal gland.
We are honored to be the first site to administer gene therapy in a patient with CAH as it is a potential game-changing treatment option that targets the disease at its source, said Kyriakie Sarafoglou, M.D., associate professor and director of the Center for Congenital Adrenal Hyperplasia at the University of Minnesota. We are eager to see whethergene therapy can restore endogenous cortisol production, and also look forward to exploring its effect on thephysiological mechanisms that regulate the hypothalamic-pituitary-adrenal axis including circadian and ultradian hormonal profiles.
BridgeBios investigational AAV5 gene therapy for CAH is one of the Companys 14 programs that are in the clinic or commercial setting for patients living with genetic diseases and cancers. Initial Phase 1/2 data readouts of the Companys AAV5 gene therapy for CAH and the Companys AAV9 gene therapy for Canavan disease are expected in the second half of 2022.
For more information about the ADventuretrial, visit ClinicalTrials.gov (NCT04783181).
About BBP-631BBP-631 is an AAV5 gene therapy developed to treat CAH due to 21-hydroxylase deficiency at its source. BBP-631 is designed to deliver a functional copy of the 21-hydroxylase gene and has been shown through multiple preclinical studies to result in efficient and persistent delivery to the adrenal gland, where hormones are naturally made. If successful, BBP-631 may restore the bodys hormone and steroid balance by enabling people with CAH to naturally make their own cortisol and aldosterone. It could also allow for people with CAH to eliminate or significantly reduce their daily glucocorticoid or mineralocorticoid doses, which is the current standard of care for patients.
About Congenital Adrenal Hyperplasia (CAH)Affecting approximately 75,000 people in the United States and European Union, CAH is a group of genetic disorders that affect the adrenal glands, which is caused by a mutation in the gene encoding for 21-hydroxylase, an enzyme essential for making the hormones cortisol and aldosterone which are critical for various physiologic functions. Cortisol is necessary for the body to respond to injury, stress or illness, and aldosterone is required to maintain proper blood pressure and sodium levels. Unable to produce cortisol and aldosterone, people with classic CAH cannot mount the healthy physiological response to stressors, such as illnesses, that allows their heart, lungs, kidneys and other organs to compensate for the stress, which can be life-threatening. These adrenal crises can be particularly dangerous for young children.
About BridgeBio Pharma, Inc.BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBios pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the companys first two approved therapies. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.
BridgeBio Pharma, Inc. Forward-Looking StatementsThis press release contains forward-looking statements. Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as anticipates, believes, estimates, expects, intends, may, plans, projects, seeks, should, will, and variations of such words or similar expressions.We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements relating to the timing and success of BridgeBios Phase 1/2 clinical trial of BBP-631 for the treatment of CAH, expectations, plans and prospects regarding BridgeBios regulatory approval process for BBP-631, the ability of BBP-631 to treat CAH in humans, and the timing and success of initial top-line Phase 1/2 date of BBP-631, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved.Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, BridgeBios ability to continue and complete its Phase 1/2 clinical trial of BBP-631 for the treatment of CAH, past data from preclinical studies not being indicative of future data from clinical trials, BridgeBios ability to advance BBP-631 in clinical development according to its plans, the ability of BBP-631 to treat CAH, the ability of BBP-631 to retain Fast Track Designation, Rare Pediatric Drug Designation, and Orphan Drug Designation from the U.S. Food and Drug Administration and Orphan Drug Designation from the European Medicines Agency, risks inherent in developing therapeutic products, the success, cost, and timing of the Companys product candidate research and development activities and ongoing and planned preclinical studies and clinical trials, the success and timing of preclinical study and clinical trial results, the success of its clinical trial designs, the fact that successful preliminary preclinical study or clinical trial results may not result in future clinical trial successes and/or product approvals, trends in the industry, the legal and regulatory framework for the industry, the success of current and future agreements with third parties in connection with the development or commercialization of the Companys product candidates and FDA-approved products, the size and growth potential of the market for the Companys product candidates and FDA-approved products, the Companys ability to access additional funding upon achievement of portfolio milestones, the accuracy of the Companys estimates regarding expenses, future revenue, future expenditures and needs for and ability to obtain additional financing, the Companys ability to be a sustainable genetic medicine innovation engine and to build the next great genetic medicine company, the Companys ability to obtain and maintain intellectual property protection for its product candidates and approved products, the competitive environment and clinical and therapeutic potential of the Companys product candidates and FDA-approved products, the Companys international expansion plans, and potential adverse impacts due to the global COVID-19 pandemic such as delays in clinical trials, preclinical work, overall operations, regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; as well as those set forth in the Risk Factors section of BridgeBios most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent SEC filings, which are available on the SECs website atwww.sec.gov.Moreover, BridgeBio operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
BridgeBio Media Contact:Grace RauhGrace.rauh@bridgebio.com(917) 232-5478
BridgeBio Investor Contact:Katherine Yaukatherine.yau@bridgebio.com(516) 554-5989
Posted in Gene Medicine
Comments Off on BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) -…
Gene therapy shows promise at treating severe form of epilepsy – Freethink
Posted: at 11:55 pm
Scientists at the University of Virginia (UVA) School of Medicine have developed a promising gene therapy to target the mutation behind a severe form of epilepsy.
The new Dravet syndrome treatment could help improve and extend the lives of people with the rare but debilitating disease.
The challenge: People born with Dravet syndrome start experiencing seizures when theyre still infants. Seizures continue throughout their lives and often lead to a host of health problems severe developmental delays, speech impairments, intellectual disability, and movement difficulties.
There is no cure for Dravet syndrome, and 10-20% of children born with it die before reaching adulthood.
Certain diets, medications, and therapies can help reduce the frequency and severity of seizures, but patients still require constant, lifelong care.
Between 10% and 20% of children born with Dravet syndome die before reaching adulthood.
The idea: In more than 80% of cases, people with Dravet syndrome have a mutation in a particular gene (called SCN1A) that results in reduced production of a critical protein in the brain.
This leads to a shortage of that protein in specialized brain cells, called interneurons, that protect against seizures.
No existing Dravet syndrome treatment directly addresses the underlying cause of the disease so the UVA team decided to make one that does.
The Dravet syndrome treatment: Dravet is usually caused by a single random mutation, but people generally carry two copies of every gene. The researchers aimed to use the second intact gene to treat the disease.
The treatment completely prevented seizures and premature death in infant mouse models of Dravet.
Using an approach they call Targeted Augmentation of Nuclear Gene Output (TANGO), the scientists developed a Dravet syndrome treatment that prompts the intact gene to increase protein production.
When tested in mouse models of Dravet syndrome, the treatment completely prevented seizures and premature death in infant mice.
The animals interneurons were more responsive, more active, and better able to do their jobs, according to a press release.
The big picture: Therapies that work in mice often fail in humans, but early results in human trials suggest this Dravet syndrome treatment has a shot.
More than 70% of children with Dravet in an ongoing phase 1/2A study experienced a reduction in seizure frequency following treatment, according to Stokes Therapeutics, the company developing the drug.
That study was small, with just 21 participants so far, and these are interim results, so its still too early to say whether the therapy (called STK-001) will ultimately make it to patients.
Still, if the results hold up in larger trials, the new treatment could help people with Dravet syndrome live longer, healthier lives.
Wed love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at tips@freethink.com.
More:
Gene therapy shows promise at treating severe form of epilepsy - Freethink
Posted in Gene Medicine
Comments Off on Gene therapy shows promise at treating severe form of epilepsy – Freethink
Scientists Surveyed People About Space. The Comments Are Out Of This World – VICE
Posted: at 11:55 pm
ABSTRACT breaks down mind-bending scientific research, future tech, new discoveries, and major breakthroughs.
The history of space exploration has never been dull, but we happen to be living through an especially eventful era of dazzling discoveries, ambitious missions, and emerging challenges.
To get a sense of how people feel about this multifaceted spacescape, Motherboard is exclusively publishing the results of a wide-ranging poll of the American public, conducted by a team at the Outer Space Institute, a transdisciplinary global network of space experts, and the Angus Reid Forum USA, an online public opinion community.
The poll, which is available to view in full at this link, queried more than 1,500 respondents about topics such as aliens, orbital debris, the United States Space Force, and human missions to the Moon and Mars. The team also invited participants to provide feedback, in their own words, on the poll, with verbatim responses that ranged in tone from wistful to conspiratorial to zany (one person, for instance, offered this simple yet incisive comment: Uranus).
The poll was conducted through an online opinion panel and was designed to be as statistically representative of the American public as possible in terms of demographics, geography, and even political affiliation. The end results offer an intriguing snapshot of public attitudes about space from the most influential spacefaring nation on Earth.
U.S. public opinion really matters in space because the United States really matters in space, said Michael Byers, a professor and Canada Research Chair in global politics and international law at the University of British Columbia (UBC), in a call with team members Aaron Boley, an associate professor and Canada Research Chair in planetary astronomy at UBC, and Gregor Sharp, senior manager of panel research and outreach at the Angus Reid Forum. (Byers and Boley also serve as co-directors of the Outer Space Institute).
As for why Canadian researchers conducted the poll, its because what [U.S. decision-makers] decide matters for everyone, added Byers.
On top of that, it's just super-interesting research that hasn't been done before, noted Sharp.
To that point, the poll revealed overwhelming consensus on a few issues. A whopping 81 percent of participants agreed that outer space should belong to everyoneno one country should be able to claim control over it, with 49 percent indicating they strongly agreed with that statement. The value of fundamental science, such as astronomy, was likewise broadly acknowledged, with 72 percent of respondents agreeing that it is important and deserves government funding (30 percent strongly agreed).
The participants also expressed high levels of optimism about the existence of alien life, as well as the odds that humans will one day encounter it. Seventy-one percent agreed it is likely that there is other intelligent life beyond Earth in our galaxy, the Milky Way, with 40 percent strongly agreeing with that statement.
Meanwhile, 75 percent said it is likely that we will detect microorganisms beyond Earth in our solar system (49 percent said very likely) while 77 percent said it is likely that we will detect microorganisms elsewhere in our galaxy (52 percent said very likely).
The broad recognition of the possibility of life in the solar system has implications for how we conduct space exploration, said Boley, who noted that it also underscores the need for planetary protection measures designed to prevent cross-contamination between Earth and other worlds.
The wide public recognition that this is something that is a real possibility is, I think, an important component of this poll, Boley added.
Byers said that some of the results were extremely helpful to the Outer Space Institutes advocacy efforts, which include a push to ban anti-satellite (ASAT) tests. These tests destroy satellites and create swarms of orbital debris, which is outer space junk made up of defunct or broken spacecraft parts.
The poll revealed strong opposition to ASAT tests and high levels of concern about orbital debris. Seventy-two percent agreed that there should be an international ban on conducting tests that create orbital debris, and 69 percent agreed that countries that create more orbital debris should be sanctioned.
These results show that the U.S. government would have public support to add its weight to the push for a test ban treaty, Byers said.
The poll also showed that the American public is wary of some commercial activities in space, and generally has nuanced opinions about the private space sector. Sixty-nine percent said there should be limits on the number of satellites that companies can launch, indicating awareness about megaconstellations, such as SpaceXs Starlink, that could add tens of thousands of satellites to orbit this decade. In addition, 54 percent of respondents said that companies should not be able to profit from resources extracted off of the planet, with 29 percent saying they should be able to profit and 17 percent saying they were unsure about this issue.
For the most part, the poll did not show a huge difference in opinion according to political affiliation. However, Americas notoriously polarized politics did manage to infect one topic: the United States Space Force.
Perhaps unsurprisingly, participants who supported Donald Trump in the 2020 presidential election were far more likely to have favorable views of this military agency, which was previously known as U.S. Air Force Space Command before Trump rebranded it. Seventy percent of those who voted for Trump in the last election agreed that the Space Force is essential for protecting American interests in outer space, compared to 33 percent of respondents who voted for Biden in 2020, and 41 percent of people who did not vote in the 2020 election.
There were other revealing nuggets lodged in the demographic details of the responses. Women were more likely than men to say they were unsure of their opinion on the presented issues, which is a gender-based trend that turns up in polls on many subjects. Sharp also pointed out that African-Americans were generally more skeptical of extravagant space missions, which may reflect, in part, the recognition of longstanding institutional racism within spaceflight, perhaps typified by the 1970 song Whitey on the Moon by Gil Scott-Heron.
Some respondents provided written feedback to the poll in a section the team called Verbatims. Sharp warned that these comments should not be viewed as representative of the American public, because they express the viewpoints of only a few individuals.
To the extent that a verbatim reflects data that we polled on, sometimes it's just a very good way to illustrate, in somebody else's words, how they think about a question that we may have abstracted or may have framed slightly differently, Sharp explained. There's the potential to link up verbatims to the overall results, but of course, proceed with caution because the way people infer or interpret things does vary.
Indeed, an interesting subset of responses referenced conspiracy theories and misinformation, though its difficult to parse whether those comments are genuine beliefs or playful trolls, according to the teamfollow-ups would be required to get a better sense of the real intent. Here are a few of those responses, some of which are edited for brevity but otherwise unaltered:
Did we really go to the Moon?
I believe its all a lie . Conspiracy theory 101
NASA is the biggest frauds besides the government. We havent been to the moon, outer space or mars. The earth is flat, not a globe. The earth being round is a massive deception that upon research is uncovered.
I just hope we really are going in outer space and the moon.Gov sure is wating alot of money in space.
I still find it strange that NASA kinda pretty much disappeared and then came back. Like what is really going on?
I think governments should be more truthful about all of it, like what's going on out there.
Was there actually a moon landing?
Humans destroy everything. We cant figure out to leave well enough alone. Lets fix Earth (and I dont even believe in the constructs of Global Warming )
China just wants to get us to spend billions....they haven't even been to the Moon......neither have we.....but I would think that anyone wishing to go to Mars would want to go to the Moon first.
Beyond mentions of conspiracies, the comments expose a kaleidoscopic array of interests and opinions about space. For instance, a significant chunk expressed concern that funding for space exploration would be better spent on social or environmental issues on Earth, while others were extremely enthusiastic about exploring outer space. Here are a few snippets of both perspectives.
I love space, space exploration, the idea of intelligent life-- I love all of it but it amounts to absolutely nothing when we have some pretty catastrophic issues here that could be solved with that money (military budgets, too!)
We should be looking for other habitable planets like earth and trying to figure out how to travel quickly, like warp drive, instead of wasting so much time on Mars that is not habitable.
Don't colonize Mars. Focus on this planet first. So many more people will suffer needlessly if we just take our societal fuck-ups to another planet, especially since so many are already suffering here. We cannot handle it.
There is no compelling reason to funnel billions of dollars into exploring space in any capacity when our planet will become unlivable within a few generations. Doing so is irresponsible and disgusting. Countries, companies, and individuals with wealth should spend their resources helping people and the earth, not getting into pissing wars over space.
The emergence of private space companies, such as SpaceX and Blue Origin, also generated a range of reactions. Some respondents welcomed the dawn of commercial spaceflight, while others voiced negative opinions of space sector billionaires like Elon Musk and Jeff Bezos. Here are some of those comments:
Billionaires are evil and have already destroyed this planet so they're looking for another to destroy, figures
I think the new private companies are doing much better than governments did to promote space exploration
I think we should spend our tax $$$ on people here on earth and stop wasting it on space projects. Let Elon Musk spend his billions on space projects if he wants to.
Limits on billionaire vanity project rocket launches- Jeff bezos should be taxed for every recreational rocket trip- perhaps to the scale of their greenhouse gas emissions.
Honestly I think if individual people are wealthy enough to go to space on their own, then however much money they spend getting there they should also have to donate to climate issues.
I hate the fact that we are now exploiting celebrities to go into space. They don't belong there. Leave space travel to the seasoned astronauts.
Another fascinating subsection of participants approached space issues through the lens of their religious beliefs:
We should be exploring Earth's waters instead of wasting so much time , money and energy on chasing outer space fantasies. If God wanted us to have other worldly neighbors he would have created them and maybe he already has!?
My biblical beliefs are that it All belongs to God, if we are to represent Him well, there needs to be a balance of protecting the USA and meeting the needs of the whole working class of earthly humans. Not just the rich assholes.
Naturally, many participants also offered their thoughts on UFOs and whether humans have already been contacted by alien life:
I've seen UFO's/UAP's 4 times in my life that I know no man had anything to do with creating or piloting. So I think more pointed questions as to one's personal experiences of whether or not we've ever witnessed a UFO/UAP would be interesting for you to know about us.
I believe that there are outer space beings. Mainly Aliens. I have seen UFO's in different areas of America.
Speaking of aliens, there was an interesting split in the comments between people who viewed extraterrestrial contact in a positive light and those that expressed concerns about the potential dangers of such an encounter:
We are not alone. We should have a global plan
Alien relations? We should decide as a planet how we interact with potentially intelligent alien life.
I think it is highly likely that we will find other intelligent life other than microorganisms out in our solar system! It is to vast and to large for us to be the only ones
If there is a race advanced enough to visit earth as often as we presume, how can we be foolish enough to think we could fight them in a battle.
Where are the smart aliens that can help us cure cancer and extend human life.
Some of the responses absolutely demand further clarification. One person suggested that people might be able to hear aliens when they smoke cannabis. Another dared to address the question on everyones mind: What about sex in zero gravity ??? Is getting pregnant there even possible ??? A participant also came up with a creative, if bittersweet, idea to immortalize humanitys existence: We should carve a carbon/carbon-dioxide molecule diagram into the moon in case humans die off because of climate change.
My personal favorite is a bit inscrutable, but I read it as a succinct suggestion: more planets. Agreed.
Overall, the combination of the poll and the verbatim responses suggest that plenty of Americans are curious about all facets of space explorationincluding completely unexpected onesand that many have strong opinions about how it should be conducted now, and in the future.
It was very pleasing to see the relatively high level of understanding of space issues, said Byers. People are plugged in.
Read the original:
Scientists Surveyed People About Space. The Comments Are Out Of This World - VICE
Posted in Space Exploration
Comments Off on Scientists Surveyed People About Space. The Comments Are Out Of This World – VICE
FDA Pulls on the Reins for Mustang’s Gene Therapy as Others Advance – BioSpace
Posted: at 11:55 pm
Shares of Mustang Biohave fallen more than 13% in premarket trading after the company announced the U.S. Food and Drug Administration had placed a hold on the companys Investigational New Drug application for its bubble boy gene therapy.
The Worcester, Mass.-based company said the regulatory agency placed a hold on the planned Phase II study pending Chemistry, Manufacturing and Controls (CMC) clearance for MB-207, Mustangs lentiviral gene therapy. Mustang intended to initiate a pivotal Phase II study to assess the gene therapys safety, tolerability, and efficacy as a potential treatment forX-linked severe combined immunodeficiency (XSCID), also known as bubble boy disease. The study would include patients who have been previously treated with a hematopoietic stem cell transplantation.
MB-207 has previously been granted Orphan Drug and Rare Pediatric Disease designations by the FDA, makingthe asset eligible for a rare pediatric disease voucher.
In addition to the planned MB-207 Phase II study, Mustang is conducting a Phase I/II XSCID study in newly diagnosed infants under the age of two with MB-107. Like MB-207, MB-107 has also been granted Rare Pediatric Disease, Orphan Drug and Regenerative Medicine Advanced Therapy designations.
Manuel Litchman, M.D., president and chief executive officer of Mustang Bio, said the company hopes to efficiently expedite the development of both MB-2017 and MB-107. He said they believe they are well positioned to address the FDAs CMC concerns.
While Mustangs gene therapy trial is temporarily prohibited from the beginning, the FDA did clear several other companies requests to begin clinical studies.
Mind Medicines LSD Formulation Moves into Phase IIb
New York-based Mind Medicines IND for a Phase IIb study of MM-120 for treatinggeneralized anxiety disorder (GAD) was given the go-ahead by the FDA. That trial had been on hold,but the hold was recently lifted after Mind Medicines address of participant monitoring protocols for the upcoming study. The Phase IIb trial is expected to begin later this year.
The company expects to enroll a total of 200 participants who will receive a single administration of up to 200 g of MM-120 or placebo. The study's primary endpoint is the reduction in anxiety symptoms for up to 12 weeks following a single administration of MM-120, a pharmacologically optimized form of LSD.
Imara Inc. Will Begin Cardiac Study in Second Quarter
Bostons Imara Inc. will begin assessing tovinontrine (IMR-687) in a Phase II studyto treatheart failure with preserved ejection fraction (HFpEF). The clinical trial is expected to begin in the second quarter of 2022. The trial will evaluate tovinontrine in approximately 170 patients 45 years of age or older with persistent HFpEF symptoms. The primary endpoint of the study will be change in NT-proBNP, with secondary endpoints that include safety and tolerability and the quality of life measures.
Tovinontrineis a highly selective and potent small-molecule inhibitor of phosphodiesterase-9 (PDE9).
Nanoscope Therapeutics Heads into Phase II with Stargardt Therapy
Texas-based Nanoscope received IND clearance from the FDA for a Phase II study of its Multi-Characteristic Opsin (MCO-010) ambient-light activatable optogenetic monotherapy. MC)-010 is being assessed as a gene therapy to restore vision in Stargardt patients. Stargardt, an inherited retinal disease, is a form of macular degeneration affecting children and adults.
Nanoscopes MCO-010 gene therapy reprograms healthy retinal cells to make them photosensitive. It uses proprietary AAV2 vectors. The Phase II trial is expected to begin in the first half of 2022.
Nanoscope is currently conducting a PhaseIIbstudy of MCO-010 for retinal pigmentosa (RP) patients. MCO-010 has received orphan drug designations from the FDA for RP and Stargardt.
SwanBio Takes Rare Disease Gene Therapy into the Clinic
Philadelphia-based SwanBiosgene therapy for the treatment of adrenomyeloneuropathy (AMN) has been cleared for a Phase I/II study. SwanBios lead candidate SBT101 is the first AAV-based gene therapy in development designed to compensate for the disease-causing ABCD1 mutation in AMN patients.
Adrenomyeloneuropathy is the adult-onset degenerative spinal cord disease that affects people with adrenoleukodystrophy, a rare, genetic and metabolic condition. The Phase I/II study will assess the safety and efficacy of the gene therapy. It is expected to begin in the second half of 2022.
Preclinical data shows that treatment with SBT101 demonstrated dose-dependent improvement of AMN disease markers in animal models. The gene therapy was also well-tolerated in non-human primates at six months post-treatment. The company said the SBT101 program builds on its ongoing natural history study of AMN.
Read the original here:
FDA Pulls on the Reins for Mustang's Gene Therapy as Others Advance - BioSpace
Posted in Gene Medicine
Comments Off on FDA Pulls on the Reins for Mustang’s Gene Therapy as Others Advance – BioSpace
International cooperation – the key to survival on Earth and in space – Room: The Space Journal – ROOM Space Journal
Posted: at 11:55 pm
Frank De Winne joined the European Space Agencys Astronaut Corps in January 2000 and made his first spaceflight to the International Space Station (ISS) in 2002 in support of the Odissea mission. He served as a flight engineer and conducted 23 experiments in life and physical sciences, some using Europes Microgravity Science Glovebox. As part of Expedition 21, in 2009, Frank became the first European commander of the ISS. One of his tasks was to operate the Stations robotic arm to dock Japans first H-II Transfer Vehicle (HTV). After his mission, he chaired the technical committee of the second EU-ESA Space Exploration Conference in Brussels in 2010. Frank became Head of ESAs European Astronaut Centre in Cologne, Germany in August 2012. Since 2017, he has been in charge of Space Station operations at ESA, and in 2020 became ESAs ISS Programme Manager. Kirill Pletner, Editor-in-Chief of ROOMs sister publication Aerospace Sphere Journal, caught up with Frank De Winne to obtain his perspective on human space exploration, from priority areas in ESAs work to a personal view on current space trends.
The European Astronaut Training Centre has three main functions. The first is of course to train the astronauts who fly to space. This includes the basic training of new ESA astronauts and mission specific training including those astronauts from the ISS partners, which includes aspects of training on ESAs Columbus module and the European Science Programme and other elements of life aboard the ISS.
The second function is to make sure that ESA astronauts are recruited in good health and stay in good health throughout their careers and during their missions. And thirdly we support the astronauts during their operations, either on the ground or while theyre on the space station, by providing crew and family support, for example.
As the ISS programme manager, Im responsible for the entire implementation of the ISS programme within the European Space Agency. This includes all the technical engineering that is required to sustain operations on the ISS and the activities of the European Astronaut Centre. In addition, I am also responsible for all the interactions with the international partners and making sure that the ISS partners can continue to deliver a successful programme.
An interesting point about the ISS is that we can use it, on the one hand, for new scientific discoveries, but also to prepare for long-term exploration activities, such as the lunar gateway and related technology demonstrations.
Another very interesting perspective is that together with the international partnership, we are trying to build and to stimulate what we call the low Earth orbit (LEO) economy. This is important because a lot of commercial companies are now also interested in working in low Earth orbit. So, in the future, we hope to continue to use LEO ourselves as customers, but also encourage an entire commercial customer base for LEO applications. This would of course reduce the cost for the agencies, which would mean that we could spend more of our resources on further exploration beyond LEO, for example to the Moon.
Overall, the training is very similar. In the ESA and NASA system, much more attention is given to the operational skills and to work in the simulators, while I think the Russian system gives more attention to the theoretical aspects. Indeed, at the end of your training in Russia you have to do an exam, while in ESA there is no formal exam but the overall performance during your training is taken into account.
The training hall at EAC in Cologne Germany.
The first published priority for ESA is to enhance the relationship with the European Commission. The European Commission today has many space programmes, the most important being Copernicus and Galileo, which are implemented by the European Space Agency. The commission has ambitions for further flagship programmes on behalf of the whole European Union and its important that we can continue to work together to implement these programmes.
The second priority is to see how space can further contribute to the general economy and how we can encourage further commercialisation in space. We see that, especially in the United States, a lot of resources are devoted to the development of space activities by private actors. The best-known examples of that are, of course, Elon Musk with SpaceX and Jeff Bezos with Blue Origin, but there are also other actors that invest a lot of money in space. So we have to see how private actors in Europe can participate in this larger space economy.
The third priority is space safety and security. This is important because our societies are increasingly dependent on our assets in space. Think about all the transportation providers that use Galileo navigation signals to find their way around. Think about all the companies and governments that use Copernicus data to enhance their productiveness, or the use of the Copernicus system in managing disasters. Its very important that we can guarantee the use of space in the future and the safety and security of all our space assets. An important element in this is, of course, the management of space debris, in other words the control and reduction of space debris.
A fourth priority is to enhance specific ESA programmes, such as the science programme which is one of the fundaments of the European Space Agency. This would include both robotic and human exploration, and one of the programmes that we will present to the ministers in 2022 is a cooperative programme with the international partners that would see the first European walking on the Moon by 2030.
And, finally, a fifth priority is to undertake a programme of internal reform within ESA to help us to implement all our programmes in the most efficient way.
Frank De Winne with Materials Science Laboratory hardware in the ISS Kibo laboratory.
ISS Russian segment including the Nauka multipurpose laboratory module (2021).
ESA today is not looking into issues of reproduction in space, but it is looking into the effects that can influence long-term survivability in space, for example for missions to Mars. Some of these aspects are of course linked to radiation, which is why ESA is investing a lot of resources in radiation monitoring that will be conducted on the gateway element.
We are also looking into counter measures for astronauts who would have to work in the microgravity environment for the long term. The most promising are related to novel exercise devices that we will test on the space station in 2024 and then hopefully fly to the gateway.
However, ESA is also doing studies for more advanced systems that could be needed in the next 20 to 30 years. For example, the agency is studying the effects of artificial gravity, together with universities and other researchers, although, as of today, we have no projects to build artificial gravity into our space stations.
International Space Station (2021).
Hosting a visit of German Chancellor Angela Merkel to EAC.
ESA has a diversity programme for the entire workforce and aims to be an inclusive employer, but as astronauts are the most visible element of our workforce, we want to have a larger diversity and inclusiveness in our astronaut corps.
Today, spacecraft and space stations are developed for people that have very specific characteristics, who are in good health and have no physical disabilities. However, it is clear that there are plenty of people in European society that have all the qualities and capabilities needed to be a good astronaut, which is why we want to have a feasibility programme to include those people that, besides their physical disability, would be fully qualified to fly to space.
For the moment, we are only looking for people that have lost the lower parts of their limbs, or are generally of short stature, a criterion based on discussions with specialists from the Paralympic committee. We really hope that some of the people with physical disabilities that we select can become fully professional astronauts.
Frank De Winne shows Luxembourg Deputy Prime Minister Etienne Schneider a mock-up of Europe s Columbus laboratory on the ISS at EAC.
Thats a difficult question. What impressed me the most during my spaceflight was how beautiful our Earth looks, but also how fragile it is. You can see how thin our atmosphere is and its only like a small sheet of paper that surrounds the enormous planet.
From the operational side, what impressed me most during my spaceflight was the first tracking and capture of the new HTV module.
I really dont have any negative things about my spaceflight except for the fact that for six months youre away from your family and your friends. Although you can talk with them on the phone, or through the video from time to time, its impossible to have close physical contact with them.
From space the lines drawn between countries are invisible. For example, it is impossible to see national borders between Belgium, Germany, Poland, Ukraine, Belarus and Russia.
The most impressive thing that Ive seen from space is that our Earth has no borders. For example, its impossible to see from space the border between Belgium, Germany, Poland, Ukraine, Belarus and Russia. This evoked for me a very strong feeling that, for some reason, we have drawn on the map of the Earth some fairly arbitrary lines that we now call borders and that today we are fighting over those lines.
We have to understand that we have only one planet, one Earth, and we are only one humanity in this immense universe. I really hope that in the future we find ways to live together on this planet as one single humanity.
Well, in recent years, the most significant developments are of course the investors in the US that have started developing private space capabilities. Think about the flights of Virgin Galactic and Blue Origin and of course, SpaceX, which has developed the Dragon Spacecraft. So we see, in the United States, a kind of space race developing between billionaires. I think this will have a very big impact on the future of space exploration.
Today, space is already available to non-professionals, but of course only if they are rich. I think sub-orbital flights will become more and more available for the less wealthy in the near future, but orbital flight will take a lot longer.
The only companies currently offering orbital flights on the commercial market are SpaceX and Axiom, and those flights are still very, very expensive. Of course, there are other options via the Russian government, including flights with Space Adventures, but they are as expensive and implemented through a government agency.
We also have to consider how we define space: do we define the flights that Jeff Bezos and Richard Branson have made as sub-orbital flights and define this as entering space, or do we confine the definition to orbital flights that circle around the Earth more than once?
SpaceX Dragon capsule delivering ISS crew.
I personally think it is unethical to implement one-way flights to Mars. We have to understand that on Mars that are no resources and we wouldnt survive, so a one-way trip to Mars would basically be a suicide trip. For this reason, I would certainly not support or fly on a one-way trip to Mars.
Commercial space station concept by Axiom.
The most important foundation that I have discovered in the 20 years that Ive worked in space is international cooperation. Throughout my time in ESA and the International Space Station programme we have faced many difficulties, but we were always able to overcome them thanks to the support of our international partners.
Lets think about the beginning of the ISS where we had the unfortunate space shuttle accident, or to some of the Russian Progress vehicles or the Soyuz that did not make it to the ISS. The partnership has been able to overcome these difficulties and the ISS is stronger than ever.
We were recently able to dock an additional element to the Russian part of the space station, the Multipurpose Laboratory Module (MLM) which carries the European Robotic Arm. This was only possible because we have thousands of people around the world who are convinced that working together is the best way forward. And despite all the political difficulties around the world today, we continue to work and provide science for the benefit of humankind every single day on the International Space Station.
Read more here:
Posted in Space Exploration
Comments Off on International cooperation – the key to survival on Earth and in space – Room: The Space Journal – ROOM Space Journal
The Cosmosphere in Hutchinson gets its own locally brewed beer Space Race Hazy IPA – The Hutchinson News
Posted: at 11:55 pm
The Cosmosphere is not expecting their new craft beer to enter space, but they are hoping those on the ground will enjoy it.
Along with Salt City Brewing Co. in Hutchinson, the Cosmosphere launched Space Race Hazy IPA during a send-off party on Monday at the Cosmosphere.
Space Race Hazy IPA celebrates the history and future of space exploration with a specially designed label. Partial proceeds from the sale of the beer and its branded merchandise support the Cosmosphere.
The brews space theme runs deep down to the hops. In recognition of this special partnership with the Cosmosphere, Salt City Brewing Co. owner Steven Petermann included a variety of hops known as Galaxy in his blend.
"The Cosmosphere approached me, and I am all about local, so anything I can do to promote excitement and support, I'm glad to be there," Petermann said.
Petermann describes the beer as aNew England-style hazy IPA. He said he uses Hutchinson water, which is vital to the taste of Space Race.
"It's very aromatic, very intense hot flavors. Juicy," he said. "This one I would describe as mango tangerine, citrusy flavors."
Petermann, who grew up on a farm near Great Bend and Holyrood, moved to Hutchinson in 1999. Now, he said, "I bleed local through and through. So anything I can do local, I'd love to be a part of."
TheCosmosphere's President and CEO Jim Remar also supports local.
"It's an opportunity for the Cosmosphere to help Salt City grow and to help the Cosmosphere brand," Remar said. "It has been a great partnership with Salt City and with the team at Howerton+White advertising in Wichita, which created the incredible graphics for Space Race."
More: Kansas' premier space museum, the Cosmosphere, gets a major facelift
Space Race is on tap at Salt City Brewing Co. tap room and through various liquor stores and distributors throughout Kansas. T-shirts, hats and pint glasses are for sale at the Cosmosphere. More information is available at spaceraceipa.com.
The Cosmosphereis a Smithsonian Affiliate. Its collection includes U.S. space artifacts second only to the Smithsonians National Air and Space Museum. The facilityalso contains the largest collection of Russian space artifacts outside of Moscow.
Located in central Kansas, this unique collection allows the Cosmosphere to tell the story of the Space Race.
Read more from the original source:
Posted in Space Exploration
Comments Off on The Cosmosphere in Hutchinson gets its own locally brewed beer Space Race Hazy IPA – The Hutchinson News